Skip to main content
Fig. 1 | BMC Health Services Research

Fig. 1

From: Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma

Fig. 1

Histograms for Medicare costs (left column) and patient out-of-pocket costs (right column) for EGFR testing (top row) and EGFR targeted therapies erlotinib (middle row) and afatinib (bottom row). A small number of patients with Medicare costs for EGFR > $8000, and out-of-pocket costs > $2000 for EGFR, erlotinib, and afatinib are not shown in the figures. The total number of patients excluded from the figures is less than 50, while the exact number of patients excluded for each group is masked per SEER-Medicare user agreement for confidentiality

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us